JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (11): 55-58.doi: 10.6040/j.issn.1671-7554.0.2015.577

• Clinical Medicine • Previous Articles     Next Articles

Changes of thrombosis molecular markers and their clinical values in type 2 diabetic patients with low extremity fractures

QIN Xiangde1, YANG Chunyun2, ZHANG Yuan3, NI Yihong4, YU Chao5, FENG Xiaoli5, XU Chengwei5   

  1. 1. Department of Orthopedic Surgery, Central Hospital of Xinwen Mining Group, Laiwu 271219, Shandong, China;
    2. Department of Laboratory Medicine Laizhou City People s Hospital, Laizhou 261400, Shandong, China;
    3. Center of Evidence-based Medicine, Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    4. Department of Endocrinology, Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    5. Department of Laboratory Medicine, Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Received:2015-06-13 Online:2015-11-10 Published:2015-11-10

PDF (PC)

417

Abstract: Objective To explore the effects of fracture on the activity of blood coagulation in patients with type 2 diabetes mellitus and the relationship between fracture and thrombotic diseases. Methods A total of 90 patients with type 2 diabetes mellitus and lower limb fracture (diabetic and fracture group), 90 patients with type 2 diabetes (diabeticgroup) and 90 healthy controls with comparable of sex, age and body mass index (control group) were recruited. The contents or activity of plasma fibrinogen (Fib), D-dimer (D-dimer), von willebrand factor (vWF), platelet membrane glycoprotein 140 (GMP-140), prothrombin fragment 1+2 (F1+2), thrombin activation of fibrinolysis inhibitor(TAFI) and tissue factor pathway inhibitor (TFPI), were compared. Results In the diabetic and facture group, the values of Fib, D-dimer, vWF, GMP-140, F1+2 and TAFI were (5.3±1.4) g/L, (1 350.1±88.3) ng/mL, (161.9±6.6) IU/dL, (21.8±2.5) μg/L, (1.6±0.5) nmol/L and (30.5±3.8) μg/mL, respectively. In the diabetic group, the values were (4.1±1.2) g/L, (880.5±35.6) ng/mL, (123.6±5.5) IU/dL, (18.9±2.3) μg/L, (1.3±0.3) nmol/L, (28.3±2.9) μg/mL, respectively. In the control group, the values were (2.5±0.6) g/L, (145.7±22.5) ng/mL, (96.8±4.5) IU/dL, (13.8±2.1) μg/L, (0.8±0.2) nmol/L, (26.4±2.5) μg/mL, respectively. The values of the former two groups were significantly higher than those of the control group, and the values of the diabetic and fracture group were higher compared to those of the diabetic group (F=141.70, 10 396.17, 3 072.95, 277.67, 116.05, 277.67, P<0.001). The plasma TFPI activity of the former two groups was lower than that of the control group (16.2±1.3, 17.3±2.1, 18.5±2.7, U/mL). And it was the lowest in the diabetic and fracture group (F=26.68, P<0.001). Conclusion Fractures can lead to blood clotting activity and high coagulation state in diabetic patients, thus such patients are prone to thromboembolic disorders.

Key words: Type 2 diabetic patients, Low extremity fractures, Coagulation molecular markers, Thrombosis

CLC Number: 

  • R446.1
[1] Morel O, Jesel L, Abbas M, et al. Prothrombotic changes in diabetes mellitus[J]. Semin Thromb Hemost, 2013, 39(5):477-488.
[2] 秦祥德, 徐成伟. 创伤性四肢骨折患者凝血纤溶指标变化[J]. 山东医药, 2010, 50(22):71-72. QIN Xiangde, XU Chengwei. Changes of coagulation and fibrinolysis indexes in patients with traumatic limbs fracture[J]. Shandong Medical Journal, 2010, 50(22):71-72.
[3] Chen SF, Xia ZL, Han JJ, et al. Increased active von Willebrand factor during disease development in the aging diabetic patient population[J]. AGE, 2013, 35(1):171-177.
[4] Ma LP, Nie DN, Hsu SX, et al. Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane b2 with pravastatin therapy for hypercholesterolemia[J]. J Assoc Acad Minor Phys, 2002, 13(1):23-26.
[5] Jax TW, Peters AJ, Plehn G, et al. Relevance of hemostatic risk factors on coronary morphology in patients with diabetes mellitus type 2[J]. Cardiovasc Diabetol, 2009, 8(24):1475-2840.
[6] Chudy P, Kotuličová D, Staško J, et al. The relationship among TAFI, t-PA, PAI-1 and F1+2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria[J]. Blood Coagul Fibrinolysis, 2011, 22(6):387-393.
[7] Chen D, Giannopoulos K, Shiels PG, et al. Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium[J]. Blood, 2004, 104(5):1344-1349. [8] Xu CW, Wu XB, Ma XL, et al. Genetic variation in thrombin- activatable fibrinolysis inhibitor (TAFI) is associated with the risk of Diabetic nephropathy[J]. J Endocrinol Invest, 2012, 35(7):620-624. [9] Xu CW, Ma XL, Zhang Y, et al. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphisms in breast cancer[J]. Blood Coagulation and Fibrinolysis, 2013, 24(7):698-703. [10] 刘延鹏, 李玲, 纪全江, 等. 非小细胞肺癌患者血浆凝血酶激活的纤溶抑制物、组织途径抑制物及凝血酶原片段1+2的水平变化及临床意义[J]. 中华检验医学杂志, 2012, 35(3):466-468. LIU Yanpeng, LI Ling, JI Quanjiang, et al. Plasma thrombin-activatable fibrinolysis inhibitor, tissue factor pathway inhibitor and fibrinopeptide 1+2 levels variation and its clinical values in patients with non-small-cell lung cancer[J]. Chinese Journal of Laboratory Medicine, 2012, 35(3):466-468. [11] 李玲, 王丽丽, 王胜江, 等. 乳腺癌患者血浆D-二聚体水平与预后关系的研究[J]. 山东大学学报:医学版, 2014, 52(9):77-80. LI Ling, WANG Lili, WANG Shengjiang, et al. Research on the relationship between plasma D-dimer level and prognosis of breast cancer patients[J]. Journal of Shandong University:Health Sciences, 2014, 52(9):77-80. [12] Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer[J]. Br J Cancer, 2002, 86(3):389-395. [13] Krupinski J, Turu MM, Font MA, et al. Increased tissue,MMP-8, and D-dimer expression in diabetic patients with unstable advanced carotid atherosclerosis[J]. Vasc Health Risk Manag, 2007, 3(4):405-412. [14] Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus[J]. Osteoporos Int, 2012, 23(2):635-641. [15] Jung JK, Kim HJ, Lee KH, et al. Fracture incidence and risk of osteoporosis in female type 2 diabetic patients in Korea[J]. Diabetes Metab J, 2012, 36(2):144-150.
[1] WANG Xiaohan, WU Xuejun, DONG Dianning, WANG Maohua, HAN Zonglin, GAO Peixian, KONG Xiangqian. Single-center experience in diagnosis and treatment of primary aortic thrombosis [J]. Journal of Shandong University (Health Sciences), 2024, 62(9): 115-124.
[2] CHENG Xuan, YANG Fan, PAN Zhenglun. Systemic lupus erythematosus, antiphospholipid syndrome with cerebral venous sinus thrombosis: a case report and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 70-74.
[3] CHEN Liyu, XIAO Juan, LYU Xianzhong, DUAN Baomin, HONG Fanzhen. Risk factors influencing prognosis of lower extremity deep vein thrombosis in pregnant and parturient women [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 38-42.
[4] WANG Ning, GUO Zhenjiang, ZHANG Yuanyuan, WANG Jing, GUO Wei, WANG Jinrong, CUI Zhaobo. Value of regular ultrasound examination in the diagnosis and treatment of deep venous thrombosis associated with central venous access device [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 63-67.
[5] LI Haiyun, QIAO Shan, CUI Caisan. A retrospective clinical analysis of 127 cases with cerebral vein sinus thrombosis [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 77-81.
[6] SUN Xinguo, CHEN Kunhao, HU Zhang, DENG Xiaojun, DUAN Shijiao, XIE Weihua, YAN Qiong, ZHANG Hongwen. Effects of mechanical thrombus aspiration and catheter-directed thrombolysis on venous function in 87 cases of acute central deep venous thrombosis of lower extremity [J]. Journal of Shandong University (Health Sciences), 2020, 58(1): 26-30.
[7] DING Yanfei, YANG Zhuoxin, ZHENG Wenwen, YUAN Wenjie, GAO Yanjing. Risk factors of portal vein thrombosis in patients with liver cirrhosis [J]. Journal of Shandong University (Health Sciences), 2018, 56(12): 13-18.
[8] WU Dayong, ZHANG Wenyan, FANG Baoshuan, QIU Gang, BIAN Yanzhu, HU Yujing. Diagnostic value of pulmonary perfusion SPECT/CT for lower-limb deep-vein thrombosis cases of patient with suspected pulmonary embolism which had different Wells scores [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(6): 86-89.
[9] LIU Yan-chun, YANG Zhi, YUAN Xiu-rong, GAO Chang, ZHANG Li-min, LIU Yong-xia.  Comparison of different thrombolysison in acute deep venous thrombosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(11): 61-63.
[10] SUN Yan, ZHANG Shi-yi, LIU Yang, JIN Xing, WANG Mo. Diagnosis and treatment of lower extremity deep venous thrombosis during the gestational period [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(10): 143-145.
[11] SUN Ping， KONG Bei-hua. Deep venous thrombosis in postpartum inpatients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(1): 104-.
[12] ZHANG Cheng-mei1, YIN Zhi-sheng1, WU Chuan-tao1, JI Jian-bo2, YU Xue-hui1, ZHANG Cheng-e3, LIU Zhao-ping1. Indobufen on platelet aggregation and thrombosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(12): 37-45.
[13] GAOYang,TIANPeng. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(5): 489-491.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd